Background. Mucosal-associated invariant T (MAIT) cells might play a role in control of viral replication during chronic hepatitis B (cHBV) infection, but little is known of their number, phenotype, or function in cHBV patients.
Chronic hepatitis B virus (cHBV) infection is a non-cytopathic
infection of the host hepatocytes affecting over 240 million people worldwide. Progression to chronicity, control of viral replication, and the degree of liver injury are determined by host immune responses [1] . For early control of viral replication as well as the generation of adaptive immune responses to HBV, local production of the antiviral cytokine interferon gamma (IFNɣ) is key [2] . In response to stimulation with IFNɑ, interleukin (IL)-12 or IL-18 released by plasmacytoid dendritic cells, or monocytes, IFNɣ is produced by innate immune cell populations, such as natural killer (NK) cells and NKT cells. When exposed to the same cytokines, mucosal-associated invariant T (MAIT) cells have recently been found to be a major intrahepatic IFNɣ-producing innate effector cell [3] . Mucosal-associated invariant T cells are T cells that express a semi-invariant T-cell receptor specific to bacterial vitamin B2 metabolites presented by major histocompatibility complex-related protein 1 (MR1). It has been proposed that, independently of MR1 binding, MAIT cells can produce IFNɣ, tumor necrosis factor (TNF), and IL-17 [4] and promote antiviral immune responses. This effect would be most prominent in MAIT cell-enriched tissues such as the intestinal mucosa and the liver, where CD161 + Vɑ7.2 + MAIT cells comprise 40% of the T cells (in liver perfusates) compared with 5%-10% in the peripheral blood [5, 6] . It is interestingly that, during infections with hepatitis C virus (HCV) and human immunodeficiency virus (HIV), MAIT cell frequencies in blood are low [7, 8] . In vivo peripheral MAIT cells have an activated phenotype, as reflected by higher expression of the activation maker CD38, but are less functional [8] . More importantly, in HCV and HIV, MAIT cell deletion and functional impairment was shown not to be reversible with antiviral therapy [7] [8] [9] . Taken into account the innate-like phenotype of the MAIT cell, and its broad range of antiviral effector functions and its tissue distribution, MAIT cells may be involved in immunity to HBV, yet no information is available on the possible effect of HBV on the MAIT cells compartment in cHBV patients. Therefore, we formulated the following research questions: (1) does the number, phenotype, and function of MAIT cells in cHBV patients differ from healthy controls; (2) does the clinical phase of HBV disease affect the MAIT cell compartment; (3) does liver inflammation, viral replication, and treatment impact the parameters? blood mononuclear cells (PBMCs) were isolated by Ficoll separation (Ficoll-Paque plus; Amersham) and stored at −150°C until used for the various assays. The 55 cHBV patients were part of 3 different cohorts (Table 1) . Patients from cohort 1a (n = 18) were sampled cross-sectionally and compared with an uninfected control group matched by gender (11 of 17 male healthy control vs 13 of 18 male HBV), age (average age was 41 in healthy control vs 43 in HBV), and ethnicity (10 of 17 healthy control vs 11 of 18 HBV infected subjects were of Asian descent). Nine of 18 cohort 1a patients were sampled a second time (cohort 1b), when they were on 3 years of nucleoside analog therapy (0.5 or 1 mg entecavir daily). Cohort 2 consisted of 31 patients with cHBV who were cross-sectionally sampled for comparison of different HBV clinical phases. Based on serum HBV deoxyribonucleic acid (DNA), alanine aminotransferase (ALT) levels, and hepatitis B e-antigen (HBeAg) presence at the time of sampling (see Supplementary Figure 1 ), patients were categorized into 4 clinical HBV phases according to international guidelines [1, 10] . Immune tolerant (IT) or HBeAgpositive infection patients had detectable serum HBeAg and repetitive normal ALT values (<40 U/L) for at least 1 year. The HBeAg-positive immune active ([IA] HBeAg-positive hepatitis) and HBeAg-negative ([ENEG] HBeAg-negative hepatitis) patients had repetitive or intermittent abnormal serum ALT (>40 U/L) values and HBV DNA levels >2000 IU/mL. Inactive carrier ([IC] HBeAg-negative infection) patients were HBeAgnegative and had both repetitive normal ALT values (<40 IU/L) and HBV DNA levels below 20 000 IU/mL for at least 1 year.
Serum ALT was measured on an automated analyzer, qualitative serum hepatitis B surface antigen (HBsAg) and HBeAg levels were measured on an Architect Abbott analyzer, and serum HBV DNA levels were measured using the COBAS AmpliPrep-COBAS TaqMan HBVv2test (CAP-CTM; Roche Molecular Systems). Cohort 3 consisted of 6 cHBV patients who underwent a core liver biopsy (18 Gauge), as part of a clinical trial (NCT02166047), while on successful nucleoside/nucleotide analog therapy (entecavir or tenofovir) at the time of sampling, resulting in undetectable HBV DNA and low ALT values.
Ethical Statement
The study was performed in concordance with the Declaration of Helsinki as adopted by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013. The institutional ethical review board of the Erasmus Medical Center approved the protocols, and written informed consent was obtained from all individuals. To determine the frequency and phenotype of MAIT cells, multicolor flow cytometry was performed (as described previously [7] ) on PBMCs with anti-CD3-Amcyan (SK7; BD Biosciences), anti-CD161-eFluor450 (HP-3G10; eBiosciences), anti-TCR Vα7.2-PE (3C10; BioLegend), anti-CD56-APC (N901; Beckman Coulter), anti-CD38-APC-efluor780 (HIT2; BD Biosciences), anti-CD25-APC (2A3; eBiosciences), anti-CD69-PeCy7 (TP1.55.3; BioLegend), anti-HLA-DR-APC-eFluor780 (LN3; eBiosciences), anti-CD57-FITC (TB-01; eBiosciences), anti-TIM-3-APC (F38-2E2; eBiosciences), anti-2B4-FITC (DM244; eBiosciences), anti-PD-1-Percp-eFluor710 (eBioJ105; eBiosciences), and CTLA-4-PeCy7 (14D3; BD Biosciences). Anti-CD3-PeCy7 (UCHT1; eBiosciences) and anti-CD38-PerCp-eFluor710 (HB7; eBiosciences) were used in cohort 2. The gates for the activation and exhaustion markers were set on internal controls, ie, the CD3-positive lymphocytes negative for the marker of interest. The PBMCs from cohorts 1 and 2 were assessed using the FACS Canto II Flow Cytometer (BD Biosciences). Of the cohort 3 patients, 18-gauge liver biopsies were collected in ice cold phosphate-buffered saline + 1% fetal calf serum and reduced to cell suspensions in a 48-well, flat bottom plate using a 1-mL syringe. The intrahepatic cells were stained in tandem with paired PBMCs using anti-CD3-PeCy7 (UCHT1), anti-CD56-APC (N901), anti-TCR Vα7.2-PE (3C10), anti-CD161-eFluor450 (HP-3G10), and Live/Deadaqua (Miltenyi) and assessed using a FACS Aria II Flow Cytometer. If less than 75 viable CD161 + Vɑ7.2 + CD3 + MAIT cells were detected during flow cytometry, the sample was excluded. All data were analyzed using FlowJo version 10.1 (Tree Star Inc).
Stimulation and Intracellular Cytokine Analysis of CD161 + Vɑ7.2 + CD3 +

Mucosal-Associated Invariant T Cells
Per well, 1 million PBMCs in a volume of 500 μL were stimulated with IL-12 (0.25 ng/mL; Miltenyi), IL-18 (10 ng/mL; R&D Systems), and CD28 monoclonal antibody (2 µg/mL; eBiosciences) with or without Escherichia coli (25 colony-forming units/leukocyte of E coli ATCC 25922 or E coli K12, fixed for 5 minutes with 1% formaldehyde) overnight for surface marker expression and intracellular cytokine production. Stimulation with 12-O-tetradecanoyl-phorbol-13-acetate ([PMA] 50 ng/ mL; Sigma) and ionomycin (500 ng/mL; Sigma) was used as a positive control. Depending on the stimulus used, after 6 hours (E coli and anti-CD28 2 µg/mL) and 21 hours (IL-12/ IL-18 and PMA/ionomycin) of stimulation, brefeldin A (10 μg/ mL; Sigma) was added to the cultures. Stimulated PBMCs were harvested after 24 hours of stimulation. The PBMCs were stained with anti-CD3-Amcyan (SK7), anti-CD161-eFluor450 (HP-3G10), and anti-TCR Vα7.2-PE (3C10). Next, cells were fixed with 2% formaldehyde, permeabilized with 0.5% saponin, and stained with anti-IFNɣ-FITC (25723.11; BD Biosciences), anti-TNF-APC (Mab11; eBiosciences), anti-granzyme-B-FITC (GB11; BD Biosciences), and anti-perforin-PerCP-Cy5.5 (dG9; eBiosciences). Cytokine-producing MAIT cells were assessed by flow cytometry (FACS Canto II).
Statistical Analysis
Data are expressed as means ± standard error of the mean, unless indicated otherwise. The data were analyzed with Prism software, version 5.0 (GraphPad Software) using the Mann-Whitney U test to compare the variables between independent groups and Wilcoxon signed-rank test for paired data groups. In all analyses, a 2-tailed P < .05 (95% confidence interval) was considered statistically significant.
RESULTS
Baseline Characteristics of Three Cohorts of Patients Infected With Chronic Hepatitis B Virus
To characterize the MAIT cell compartment of HBV patients in various clinical phases and during different treatment modalities, we included 3 different cohorts (Table 1) . Although different ethnicities were included, most of the patients were of Asian ancestry (65%), as reflected by the high frequencies of HBV genotypes B and C. The majority of patients (71%) was male. Representative of the Dutch HBV-infected population, patients in the asymptomatic IT phase had a relatively high percentage of female subjects (due to past HBsAg screening at time of suspected pregnancy). Virologic parameters differed between cohorts, owing to the selection criteria. At baseline of cohort 1b, the average HBV DNA was 2.5 × 10 7 IU/mL (2.9 × 10 2 -2.2 × 10 8 IU/mL), and all patients responded to nucleoside analog treatment (response was defined as undetectable HBV DNA viral loads 3 months after start of therapy). As presented in Supplementary Figure 1 , cHBV patients were selected on the basis of the level of HBV DNA, ALT, and HBeAg in serum, as described previously [11, 12] . In line with literature, HBeAgpositive patients (IT and IA patients, cohort 2) had higher HBsAg values compared with ENEG patients (averaging 5.7 × 10 8 and 7.5 × 10 5 IU/mL, respectively) [13, 14] . To explore the possible role of MAIT cells during immune responses in cHBV infection, we assessed their phenotype and frequency and compared it to a matched healthy control group. In contrast to HCV and HIV patients [6, 7] , cHBV patients did not have significantly different MAIT cell frequencies in blood within the T-cell population compared with healthy controls (averaging 2.9% and 3.7%, respectively) ( Figure 1 ). It is interesting to note that a larger fraction of MAIT cells in blood of cHBV patients expressed the activation marker CD38 on their surface in comparison to healthy controls (7.9% vs 4.6%, P = .0146). Upon further exploration of MAIT activation and/or exhaustion, we did not observe significant differences in MAIT cell percentages positive for CD25, HLA-DR, CD69, TIM-3, 2B4, CTLA-4, or PD-1 compared with controls ( Supplementary Figure 2, Supplementary Figure 3 , and summarized in Supplementary Table 1 ). The mean fluorescence intensity of CD57 on MAIT cells was significantly higher in the HBV group, mainly due to 2 HBV-infected subjects with exceptionally high CD57 expression. Upon functional assessment of MAIT cells stimulated with IL-12/IL-18/E coli, no differences were observed in the frequency of IFNɣ-producing MAIT cells in blood from HBV patients compared with healthy controls (26.9% vs 28.4%, respectively) ( Figure 2B ) and was significantly higher in the HBV group upon anti-CD28/E coli stimulation (19.2% vs 9.2%, respectively; P = .0097) ( Figure 2C ). For the evaluation of the frequency of TNF, granzyme B, and perforin producing MAIT cells, the PBMCs of 10 HBV-infected subjects and 12 healthy controls were stimulated. The potential of MAIT cells to produce TNF and perforin did not differ, but the percentage of granzyme B producing MAIT cells was higher in the HBV-infected group compared with healthy controls (upon E coli: 11.6% vs 3.3% and anti-CD28/E coli: 14.0% vs 3.7%). In the unstimulated condition, a high percentage of MAIT cells was positive for granzyme B in 3 HBV-infected patients, indicative of an activated phenotype (Figure 2A ). The cytokine-producing potential (IFNɣ, TNF) and positivity for granzyme B and perforin of MAIT cells was not significantly different upon PMA/ ionomycin stimulation (Supplementary Figure 4) . Escherichia coli-only stimulation did not or only mildly increased the frequency of granzyme B-positive cells; induction of granzyme B in MAIT cells seems to require a stronger stimulus such as IL-12/IL-18 or PMA/ionomycin (shown in Supplementary  Figure 4) . Three healthy controls and 3 HBV samples were excluded because less than 75 MAIT cells were detected (resulting in unreliable percentages of IFNɣ-positive MAIT cells).
Chronic Hepatitis B Virus Patients in the Hepatitis B e-Antigen-Negative Clinical Phase Have Lower Frequencies of Cluster of Differentiation
38-Positive Mucosal-Associated Invariant T Cells Compared With the
Inactive Carrier Phase
To investigate whether the frequency or activation of MAIT cells was related to the degree of liver inflammation or viral replication in cHBV patients, we assessed the frequency and CD38-positive percentages of MAIT cells in blood of patients at the various clinical phases. As shown in Figure 3 , MAIT frequencies did not vary significantly in patients in the IT, IA, IC, and ENEG phase (average 1.7%, 0.8%, 1.4%, and 2.1% of total CD3 + T cells, respectively), although a trend was observed for lower MAIT cell numbers in the IA phase. These phases correspond to patients with (1) HBeAg-positive infection or hepatitis and (2) HBeAg-negative infection or hepatitis, respectively, as described in recent EASL guidelines [10] . Using a longitudinal study design, we then investigated the effect of nucleoside analog treatment on MAIT frequencies and activation in 9 male patients with cHBV using paired samples. At baseline, 2 patients were in the IA phase, 1 in the IC phase, and 6 in the ENEG phase. As shown in Figure 4A , the frequency of peripheral MAIT cells was not influenced in patients on antiviral therapy for approximately 3 years, but the percentage of CD38 + MAIT cells (11.2%) declined to healthy control levels (5.4%). In line with this finding, the capacity of MAIT cells to produce IFNɣ after stimulation with IL-12/IL-18 and IL-12/ IL-18/E coli was higher in 4 of 6 patients before treatment than on treatment ( Figure 4B ), but this was a nonsignificant trend (upon IL-12/IL-18: 12.6% vs 8.3%, respectively; and upon IL-12/IL-18/E coli: 20.6% vs 16.2%, respectively). Interferonɣ production was not tested in 3 samples due to the unavailability of sufficient cells at both timepoints. We had the unique opportunity to examine liver and blood samples of 6 HBV patients on continuous nucleoside analog treatment with either entecavir or tenofovir. We observed that the MAIT cell frequencies of total T cells among individual patients varied considerably in both the intrahepatic (range, 6.4%-29.2%) and peripheral (range, 0.8%-4.8%) compartment but are highly enriched in the liver ( Figure 5 ).
DISCUSSION
To the best of our knowledge, we present the first characterization of MAIT cells in cHBV patients, during its highly variable natural history and during antiviral treatment. We show that MAIT cells are not deleted in blood of cHBV-infected patients and have a more activated phenotype that is reversible with nucleoside analog treatment. In the ENEG phase of cHBV, MAIT cells are least activated. In addition, in the majority of patients, antiviral treatment negatively impacts IFNɣ production by MAIT cells. These observations improve our understanding of the role MAIT cells during immune responses to HBV. One of our major findings is that in cHBV patients, MAIT cell frequencies are not diminished in the peripheral blood, which is in sharp contrast to various other chronic viral and inflammatory diseases [7, 15, 16] . In HCV infection, low percentages of peripheral MAIT cells in blood have been found by us and others [7, 8] . Migration towards mucosal surfaces in HIV and possibly towards the liver in HCV could explain these low peripheral frequencies. Mucosal-associated invariant T cells have been reported to home to inflamed tissues and may undergo activation-induced apoptosis when exposed to high antigen loads [16, 17] . We have previously shown that in cHBV patients with low levels of viral replication and low degrees of liver inflammation (ICs), serum levels of several proinflammatory cytokines such as IFNγ-inducible protein-10, IL-18, and IL-12p40 are low [18] . Based on the low peripheral IL-18 and IL-12p40 titers we found in this projects, we expected low percentages of CD38-positive MAIT cells in this phase. Contrary to our expectations, we observed that relatively high numbers of MAIT cells derived from ICs were CD38-positive, in particular in comparison to ENEG patients. It is possible that activated MAIT cells exit the blood and home to the liver during the immunologically more active ENEG phase. Contrary to HIV and HCV infection, the activated MAIT cell phenotype in cHBV patients was reversible with antiviral treatment. Because HBsAg levels in serum are barely affected by nucleoside analog therapy, HBsAg is unlikely to influence the release of MAIT stimulatory signals in cHBV patients. In line with the normalization of MAIT phenotype, we observed a decline of the frequency of IFNɣ-producing MAIT cells after viral suppression in the majority of treated patients, possibly due to changes in the stimulatory milieu after cessation of viral replication [19] . Indeed, after stimulation with E coli or medium only, the percentage of granzyme B + MAIT cells derived from HBVinfected patients was higher than matched healthy controls, possibly as a result of their increased activation status. None of the stimulations of MAIT cells (E coli, PMA/ionomycin, IL-12/ IL-18/E coli) showed a significant difference of the frequency of IFNɣ-positive MAIT cells between healthy controls and HBV patients, except for E coli/anti-CD28. The latter stimulus resulted in higher frequencies of IFNɣ-positive MAIT cells in HBV-infected patients. We did not examine whether MAIT cells from HBV patients have higher expression of CD28 on their surface and are therefore more responsive. In addition, the biological significance of this finding is not clear, because it was not observed for the other stimuli. However, this finding clearly demonstrates that, in contrast to other chronic viral infections, IFNɣ production is not impaired compared with healthy controls. The biological relevance of the finding requires more detailed studies to determine whether MAIT cell-derived IFNɣ may contribute to antiviral responses to HBV infection and affect fibrogenesis. The liver biopsies analyzed by flow cytometry revealed that MAIT cells remain highly enriched in the liver during nucleoside analog therapy and in the absence of liver inflammation. These biopsies indicate that although MAIT cells are known to home to inflamed tissues, ongoing local inflammation may not be necessary for their continuing presence in the liver of HBV patients. It should be noted here that a small fraction of the intrahepatic (or tissue resident) CD161 + Vɑ7.2 + CD3 + MAIT cells may be tetramer negative and therefore are not genuine MAIT cells, as has previously been suggested by Reantragoon et al [20] , and future studies should include MR1 tetramer stainings, preferably combined with the evaluation of activation and exhaustion markers.
CONCLUSIONS
In cHBV patients, contrary to chronic HCV or HIV patients, peripheral MAIT cells are not deleted in blood. Significantly more MAIT cells from HBV patients are CD38-positive compared with healthy controls. It is interesting to note that antiviral therapy normalizes the frequency of CD38-positive MAIT cells to healthy control levels, but this does not affect the relative numbers of IFNɣ-producing cells. In patients on continuous nucleoside analog treatment, we show that MAIT cells were consistently enriched in the liver, compared with the peripheral blood. These observations may aid in deciphering the role of MAIT cells in immune responses to HBV.
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